Xing Technologies Pty Ltd v Integrated Clinical Oncology Network Pty Ltd

Link copied
Case Copied 42 min read

FEDERAL COURT OF AUSTRALIA

Xing Technologies Pty Ltd v Integrated Clinical Oncology Network Pty Ltd [2017] FCA 1495

File number: QUD 252 of 2017
Judge: BESANKO J
Date of judgment: 12 December 2017
Catchwords:

PRACTICE AND PROCEDURE – consideration of an application for pre-action discovery under r 7.23 of the Federal Court Rules 2011 (Cth) – where the prospective applicant alleges the prospective respondent has engaged in misleading and deceptive conduct by making a false statement about the death of a patient in a complaint to the University of Queensland – where the prospective applicant seeks documents relevant to the prospective respondent’s intention in making the complaint – where the documents sought are not said to be relevant to any other element of the causes of action identified by the prospective applicant – where the prospective respondent’s intention is not an essential element of the claim for misleading and deceptive conduct – where the elements of causation and loss and damage are not so weak as to lead to the conclusion that the requirements in r 7.23(1)(a) of the Rules are not met.

PRACTICE AND PROCEDURE – where the prospective applicant alleges the prospective respondent has committed the tort of intentionally procuring or inducing a breach of contract – whether the prospective applicant has reasonable grounds to believe that it has the right to obtain relief in relation to this cause of action – where the prospective applicant has not identified a breach of contract by the University of Queensland or Uniquest Pty Ltd which has caused loss or damage to the prospective applicant.

PRACTICE AND PROCEDURE – whether the prospective applicant has adduced all the information they have in relation to the claims – where a final report of the Research Misconduct Inquiry was not put before the Court, on the explanation that the prospective applicant was not at liberty to disclose the report without permission from the University of Queensland.

Legislation:

Competition and Consumer Act 2010 (Cth), Schedule 2, s 18

Federal Court Rules 2011 (Cth) r 7.23

Cases cited:

Allstate Life Insurance Company and Others v Australia and New Zealand Banking Group Ltd and Others (1995) 58 FCR 26

Apache Northwest Pty Ltd v Newcrest Mining Ltd (2009) 182 FCR 124

Cadbury Schweppes Pty Ltd and Others v Pub Squash Co Ltd [1981] RPC 429

Campomar Sociedad, Limitada and Another v Nike International Limited and Another (2000) 202 CLR 45

Daebo Shipping Company Ltd v The Ship Go Star (2012) 207 FCR 220

D C Thomson & Co Ltd v Deakin [1952] Ch 646

Ebos Group Pty Ltd v Team Medical Supplies Pty Ltd [2011] FCA 862

Glencore International AG v Selwyn Mines Limited [2005] FCA 801; (2005) 223 ALR 238

Gould and Another v Vaggelas and Others (1985) 157 CLR 215

Henville and Another v Walker and Another (2001) 206 CLR 459

Hornsby Building Information Centre Proprietary Limited v Sydney Building Information Centre Limited (1978) 140 CLR 216

I & L Securities Pty Limited v…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Xing Technologies Pty Ltd v Integrated Clinical Oncology Net... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2017] FCA 1495
Decision Date

CaseChat Overview and Summary

In the case of Xing Technologies Pty Ltd v Integrated Clinical Oncology Network Pty Ltd, the applicant sought pre-action discovery of certain documents from the respondent, primarily to understand the respondent's intention in making a complaint to the University of Queensland. The applicant alleged that the respondent had made a false statement about the death of a patient in the complaint, constituting misleading and deceptive conduct. The applicant also alleged that the respondent had intentionally procured or induced a breach of contract, though it failed to identify a specific breach that caused loss or damage.

The court was required to decide whether the applicant had reasonable grounds to believe that it had the right to obtain relief in relation to the alleged misleading and deceptive conduct. Additionally, the court needed to assess if the applicant had identified a breach of contract by the University of Queensland or Uniquest Pty Ltd, which caused loss or damage. The court also had to determine if the applicant had adduced all the information it had in relation to the claims, including why a final report of the Research Misconduct Inquiry was not presented.

The court concluded that the applicant did not have reasonable grounds to believe it had the right to obtain relief in relation to the misleading and deceptive conduct claim because the respondent's intention in making the complaint was not an essential element of the claim. The court found that the elements of causation and loss and damage were not so weak as to lead to the conclusion that the requirements in r 7.23(1)(a) of the Federal Court Rules 2011 (Cth) were not met. The applicant had also not identified a breach of contract by the University of Queensland or Uniquest Pty Ltd that caused loss or damage. Consequently, the court dismissed the application. The court noted that there appeared to be no reason why costs should not follow the event but gave the parties the opportunity to address that issue.

Orders

Orders of the court

1. The application be dismissed.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

The documents which Xing seeks are documents which fall into the following categories:(a)a copy of all documents exchanged between ICON and UQ in relation to the ICON complaint and the matter raised therein;(b) a copy of all Board Minutes, Agendas and Board Documents:(i)connected to the decision by the Board of ICON to make the complaint; and/or(ii) referring to Xing;(c)a copy of all email communications between members of the Board of ICON and its officers, contractors and clinicians, in relation to investigations by ICON into the QA1 and QA2 studies, being the subject of the ICON complaint to UQ and the matter raised therein;(d)a copy of all email communications between members of the Board of ICON and officers, contractors and clinicians, in relation to the ICON complaint and the matter raised therein;(e)copies of all email communication between members of the Board of ICON and officers, contactors (sic) and clinicians, in respect of Xing.It is important to note that the documents sought by Xing are said by it to be relevant to ICON’s intention in making the ICON complaint and, in particular, the statement about the death of a patient. They are not said by Xing to be relevant to any other element of the causes of action identified by it.THE RELEVANT FACTS A summary of the relevant facts is as follows. A number of facts are established by the documents and are not in dispute. I am not making findings as to disputed facts at this stage. I will set out the events in chronological order, save that I will deal with the facts relating to the Xing Contract Ban and the damage Xing claims that it has suffered separately at the end of this section. On or about 17 December 2014, ICON advised Dr Mainwaring that it was seeking information about a number of matters concerning the QA1 study. Those matters were identified by ICON as follows:(1)Whether the research was being conducted on ICON premises;(2)Whether the research had been approved by the ICON Cancer Research Foundation Management Committee (ICON Research Committee);(3)The patient information consent sheets; and(4)The declarations of financial interests in commercial activities required as part of the research. On 27 January 2015, Dr Mainwaring provided to ICON the relevant ethics documents, including the original approval, progress reports and extension approvals. At about this time, Dr Mainwaring commenced preparing to submit QA2 to the ICON Research Committee. On 9 February 2015, ICON advised Dr Mainwaring that it had established a review panel to address a number of complaints. ICON sent Dr Mainwaring a number of questions for him to address. The second paragraph of ICON’s letter identifies in general terms its concerns at that stage. It is as follows:It is my understanding that the above study has not been approved by the Icon Cancer Foundation Research Management Committee (ICFRMC) and a number of patients have received clinical interventions as a result of the QAP research study. In addition, to the (sic) these issues we need to confirm that no other studies are being undertaken without ICFRMC approval at Icon facilities and address the declaration of conflicts of interest with Bellberry and patient participants.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

In view of this conclusion, it is not necessary to consider whether an order could be made under r 7.23(1) where the requirements of the rule are met only in relation to a non-federal claim (Apache Northwest v Newcrest Mining at [76] per Flick J).CONCLUSION In my opinion, the application should be dismissed. There appears to be no reason why costs should not follow the event, but I will give the parties the opportunity to address that issue.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.